In a report released on December 28, Mark Massaro from BTIG maintained a Buy rating on BioNano Genomics (BNGO – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $1.89.
According to TipRanks, Massaro is an analyst with an average return of -15.6% and a 33.00% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Ginkgo Bioworks Holdings, and Cerus.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNano Genomics with a $6.33 average price target.
See today’s best-performing stocks on TipRanks >>
BNGO market cap is currently $73.41M and has a P/E ratio of -0.27.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNano Genomics (BNGO) Company Description:
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Read More on BNGO:
- Bionano Genomics upgrades optical genome mapping pipeline
- Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
- Bionano Genomics announces publication comparing OGM to CMA and KT
- Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
- Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research
